- Microsoft has selected Pangaea to showcase during the HLTH conference in Las Vegas from Nov 13-16th 2022, booth 1858-9
- Pangaea will also be exhibiting and presenting at BioTechX conference in Basel from Nov 8-10th, booth 41
With a joint global go-to-market co-selling strategy, the Microsoft co-sell program enables Pangaea to work together with Microsoft’s sales organization to rapidly accelerate the sales and usage of Pangaea’s novel AI-driven product on Microsoft Azure.
Dr Vibhor Gupta, CEO and Founder of Pangaea, said: “We launched Pangaea to help improve patient outcomes by providing clinicians across the global pharmaceutical and healthcare industry the ability to characterize patient journeys and disease trajectories by unlocking and summarizing clinical insights from their records in a privacy-preserving and scalable manner. Achieving co-sell ready status reflects our growing relationship with Microsoft through the value we have generated for clinicians and patients since joining the Microsoft for Startups program. We are proud of this accomplishment, which will help us accelerate and scale our work across the pharmaceutical industry and healthcare providers in a privacy-preserving manner.”
Sally Frank, Worldwide Lead, Healthcare and Life Sciences at Microsoft for Startups, said: “We are excited to have Pangaea as a co-sell ready partner, a status which the Company has achieved in record time, and for its product to be transactable through the Azure marketplace. Pangaea continues to demonstrate its value for the healthcare and life science industry. We want to contribute and be part of the Company’s journey so that we can help clinicians as they process more patient data in a secure and compliant manner on Azure.”
Register to meet Pangaea at the HLTH conference from November 13th - 16th here.
